Europe Microbiome Therapeutics Market Forecast to 2030 - Regional Analysis - by Type (Therapeutics and Procedure), Application (Metabolic Disorder and Obesity, C. Difficile Infection, Inflammatory Bowel Disease, and Others), and End User (Hospitals and Clinics, Ambulatory Surgical Centers, Homecare, and Others)
Inflow of Funds to Ameliorate Microbiome Discovery Pipeline Drives Europe Microbiome Therapeutics Market
Research has shown that imbalances or disruptions in the microbiome can contribute to various conditions, such as inflammatory bowel disease and obesity, as well as mental health disorders. The recognition of the microbiome's role in overall health has generated significant interest in developing therapeutics to target and modulate the microbiome. Additionally, advancements in technology and research tools have made it easier to study and manipulate the microbiome. Next-generation sequencing and metagenomic analysis have allowed for a deeper understanding of microbial communities and their functions. The increased knowledge has opened up new possibilities for developing targeted therapies. For instance, in March 2023, mbiomics GmbH, a German microbiome biotech company, developed the first generation of effective microbiome-based therapeutics. It received a funding of 13 million (US$ 15 million) from MIG Capital. The funding will allow to build the platform, which will accelerate the identification of first-lead drug candidates and speed up research efforts toward clinical validation. As strong clinical evidence becomes available, investors are beginning to take notice of microbiome modulator firms. The heightened funding provides companies with necessary resources to overcome the challenges associated with the high cost of development and production, ultimately driving the field forward.
Europe Microbiome Therapeutics Market Overview
Microbiome therapeutic research companies in Germany are focused on calling other companies to invest in their research activities to improve the quality of research being conducted for microbiome product development. In March 2023, mbiomics GmbH, a German biotech company focused on the microbiome, received ~US$ 15 million (13 million) in a series A financing round led by MIG Capital. mbiomics used the proceeds to embark on strategic partnerships, significantly expanding their Munich laboratory facilities and R&D teams in Germany. In some FMT procedures, infectious agents may be transferred from donor to patient, which affects the outcomes. Hence, Germany has set particular regulations for the use of microbiome or FMT procedures. In Germany, FMT drugs are regulated as a medicinal product; however, the use of this product can be done only when no other treatment is working on conditions such as C. difficile infections and gut infections. Hence, despite an upsurge in investments in research on microbiome therapeutics, regulations regarding the use of these therapeutic products may hamper the growth of the Europe microbiome therapeutics market in Germany.
Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Million)
Europe Microbiome Therapeutics Market Segmentation
The Europe microbiome therapeutics market is segmented based on type, application, end user, and country.
Based on type, the Europe microbiome therapeutics market is bifurcated into therapeutics and procedure. The procedure segment held a larger share in 2022. The therapeutics segment is further subsegmented into fecal microbiota transplantation (FMT), prebiotics & probiotics, and others.
By application, the Europe microbiome therapeutics market is segmented into metabolic disorder and obesity, C. difficile infection, inflammatory bowel disease, and others. The metabolic disorder and obesity segment held the largest share in 2022.
By end user, the Europe microbiome therapeutics market is hospitals and clinics, ambulatory surgical centers, homecare, and others. The hospitals and clinics segment held the largest share in 2022.
Based on country, the Europe microbiome therapeutics market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe microbiome therapeutics market in 2022.
Caelus Health BV, Enterome SA, Ferring Holdings SA, Vedanta Biosciences Inc, and YSOPIA Bioscience SA are some of the leading companies operating in the Europe microbiome therapeutics market.
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Microbiome Therapeutics Market Landscape
4.1 Overview
4.2 Europe PEST Analysis
5. Europe Microbiome Therapeutics Market - Key Industry Dynamics
5.1 Europe Microbiome Therapeutics Market - Key Industry Dynamics
5.2 Key Market Drivers
5.2.1 Potential of Gut Microbiota in Maintaining Human Health
5.2.2 Inflow of Funds to Ameliorate Microbiome Discovery Pipeline
5.3 Key Market Restraints
5.3.1 High Cost of Development and Production
5.4 Key Market Opportunities
5.4.1 Increasing R&D to Gain Better Understanding of Human Microbiome
5.5 Key Future Trends
5.5.1 Technological Advancement in Human Microbiome Therapeutics
5.6 Impact of Drivers and Restraints:
6. Microbiome Therapeutics Market - Europe Market Analysis
7. Europe Microbiome Therapeutics Market Analysis - Type
7.1 Therapeutics
7.1.1 Overview
7.1.2 Therapeutics Market, Revenue and Forecast to 2030 (US$ Thousand)
7.2 Procedure
7.2.1 Overview
7.2.2 Procedure Market, Revenue and Forecast to 2030 (US$ Thousand)
8. Europe Microbiome Therapeutics Market Analysis - Application
8.1 Metabolic Disorder and Obesity
8.1.1 Overview
8.1.2 Metabolic Disorder and Obesity Market, Revenue and Forecast to 2030 (US$ Thousand)
8.2 C. Difficile Infection (CDI)
8.2.1 Overview
8.2.2 C. Difficile Infection (CDI) Market, Revenue and Forecast to 2030 (US$ Thousand)
8.3 Inflammatory Bowel Disease
8.3.1 Overview
8.3.2 Inflammatory Bowel Disease Market, Revenue and Forecast to 2030 (US$ Thousand)
8.4 Others
8.4.1 Overview
8.4.2 Others Market, Revenue and Forecast to 2030 (US$ Thousand)
9. Europe Microbiome Therapeutics Market Analysis - End User
9.1 Hospitals and Clinics
9.1.1 Overview
9.1.2 Hospitals and Clinics Market, Revenue and Forecast to 2030 (US$ Thousand)
9.2 Ambulatory Surgical Centers
9.2.1 Overview
9.2.2 Ambulatory Surgical Centers Market, Revenue and Forecast to 2030 (US$ Thousand)
9.3 Homecare
9.3.1 Overview
9.3.2 Homecare Market, Revenue and Forecast to 2030 (US$ Thousand)
9.4 Others
9.4.1 Overview
9.4.2 Others Market, Revenue and Forecast to 2030 (US$ Thousand)
10. Europe Microbiome Therapeutics Market - Country Analysis
10.1. Europe Microbiome Therapeutics Market Revenue and Forecasts and Analysis - By Country
10.1.1 Europe Microbiome Therapeutics Market Revenue and Forecasts and Analysis - By Country
10.1.2 UK
10.1.2.1 UK: Europe Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
10.1.2.2 United Kingdom Europe Microbiome Therapeutics Market Breakdown by Type
10.1.2.2.1 UK: Europe Microbiome Therapeutics Market Breakdown by Therapeutics
10.1.2.3 UK: Europe Microbiome Therapeutics Market Breakdown by Application
10.1.2.4 UK: Europe Microbiome Therapeutics Market Breakdown by End User
10.1.3 Germany
10.1.3.1 Germany: Europe Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
10.1.3.2 Germany: Europe Microbiome Therapeutics Market Breakdown by Type
10.1.3.2.1 Germany: Europe Microbiome Therapeutics Market Breakdown by Therapeutics
10.1.3.3 Germany: Europe Microbiome Therapeutics Market Breakdown by Application
10.1.3.4 Germany: Europe Microbiome Therapeutics Market Breakdown by End User
10.1.4 France
10.1.4.1 France: Europe Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
10.1.4.2 France: Europe Microbiome Therapeutics Market Breakdown by Type
10.1.4.2.1 France: Europe Microbiome Therapeutics Market Breakdown by Therapeutics
10.1.4.3 France: Europe Microbiome Therapeutics Market Breakdown by Application
10.1.4.4 France: Europe Microbiome Therapeutics Market Breakdown by End User
10.1.5 Italy
10.1.5.1 Italy: Europe Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
10.1.5.2 Italy: Europe Microbiome Therapeutics Market Breakdown by Type
10.1.5.2.1 Italy: Europe Microbiome Therapeutics Market Breakdown by Therapeutics
10.1.5.3 Italy: Europe Microbiome Therapeutics Market Breakdown by Application
10.1.5.4 Italy: Europe Microbiome Therapeutics Market Breakdown by End User
10.1.6 Spain
10.1.6.1 Spain: Europe Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
10.1.6.2 Spain: Europe Microbiome Therapeutics Market Breakdown by Type
10.1.6.2.1 Spain: Europe Microbiome Therapeutics Market Breakdown by Therapeutics
10.1.6.3 Spain: Europe Microbiome Therapeutics Market Breakdown by Application
10.1.6.4 Spain: Europe Microbiome Therapeutics Market Breakdown by End User
10.1.7 Rest of Europe
10.1.7.1 Rest of Europe: Europe Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
10.1.7.2 Rest of Europe: Europe Microbiome Therapeutics Market Breakdown by Type
10.1.7.2.1 Rest of Europe: Europe Microbiome Therapeutics Market Breakdown by Therapeutics
10.1.7.3 Rest of Europe: Europe Microbiome Therapeutics Market Breakdown by Application
10.1.7.4 Rest of Europe: Europe Microbiome Therapeutics Market Breakdown by End User
11. Industry Landscape
11.1 Overview
11.2 Growth Strategies in Europe Microbiome Therapeutics Market
12. Company Profiles
12.1 YSOPIA Bioscience SA
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Ferring Holdings SA
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Enterome SA
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Caelus Health BV
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Vedanta Biosciences Inc
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
List of Tables
Table 1. Europe Microbiome Therapeutics Market Segmentation
Table 2. Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousand) - Type
Table 3. Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousand) - Therapeutics
Table 4. Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousand) - Application
Table 5. Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousand) - End User
Table 6. Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Country
Table 7. UK: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
Table 8. UK: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
Table 9. UK: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
Table 10. UK: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
Table 11. Germany: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
Table 12. Germany: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
Table 13. Germany: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
Table 14. Germany: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
Table 15. France: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
Table 16. France: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
Table 17. France: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
Table 18. France: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
Table 19. Italy: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
Table 20. Italy: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
Table 21. Italy: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
Table 22. Italy: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
Table 23. ADULT OBESITY, 2030
Table 24. CHILD OBESITY, 2030
Table 25. Spain: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
Table 26. Spain: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
Table 27. Spain: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
Table 28. Spain: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
Table 29. Rest of Europe: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
Table 30. Rest of Europe: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
Table 31. Rest of Europe: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
Table 32. Rest of Europe: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
Table 33. Recent Growth Strategies in Europe Microbiome Therapeutics Market
Table 34. Glossary of Terms, Europe Microbiome Therapeutics Market
List of Figures
Figure 1. Europe Microbiome Therapeutics Market Segmentation, By Country
Figure 2. Europe PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Europe Microbiome Therapeutics Market Revenue (US$ Thousand), 2022 - 2030
Figure 5. Europe Microbiome Therapeutics Market Share (%) - Type, 2022 and 2030
Figure 6. Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousand)
Figure 7. Procedure Market Revenue and Forecasts To 2030 (US$ Thousand)
Figure 8. Europe Microbiome Therapeutics Market Share (%) - Application, 2022 and 2030
Figure 9. Metabolic Disorder and Obesity Market Revenue and Forecasts To 2030 (US$ Thousand)
Figure 10. C. Difficile Infection (CDI) Market Revenue and Forecasts To 2030 (US$ Thousand)
Figure 11. Inflammatory Bowel Disease Market Revenue and Forecasts To 2030 (US$ Thousand)
Figure 12. Others Market Revenue and Forecasts To 2030 (US$ Thousand)
Figure 13. Europe Microbiome Therapeutics Market Share (%) - End User, 2022 and 2030
Figure 14. Hospitals and Clinics Market Revenue and Forecasts To 2030 (US$ Thousand)
Figure 15. Ambulatory Surgical Centers Market Revenue and Forecasts To 2030 (US$ Thousand)
Figure 16. Homecare Market Revenue and Forecasts To 2030 (US$ Thousand)
Figure 17. Others Market Revenue and Forecasts To 2030 (US$ Thousand)
Figure 18. Europe Microbiome Therapeutics Market Breakdown by Key Countries - Revenue (2022) (US$ Thousand)
Figure 19. Europe Microbiome Therapeutics Market Breakdown by Key Countries, 2022 and 2030 (%)
Figure 20. UK: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)
Figure 21. Germany: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)
Figure 22. France: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)
Figure 23. Italy: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)
Figure 24. Spain: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)
Figure 25. Rest of Europe: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)
1. Caelus Health BV
2. Enterome SA
3. Ferring Holdings SA
4. Vedanta Biosciences Inc
5. YSOPIA Bioscience SA